Nasdaq

First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative ...

Previous Phase 1b clinical data suggest niclosamide delivers favorable efficacy compared to topical corticosteroid in the treatment of ulcerative proctitis and ulcerative proctosigmoiditis BOCA RATON, ...
FierceBiotech

Salix Pharmaceuticals Announces Statistically Significant Results for Budesonide Foam in the Treatment of Active Mild to Moderate Ulcerative Proctitis or Ulcerative ...

<0> Salix Pharmaceuticals, Ltd.Adam C. DerbyshireExecutive Vice President and Chief Financial OfficerorG. Michael FreemanAssociate Vice President, Investor Relations and Corporate ...
Monthly Prescribing Reference

Significant Results for Budesonide Foam in Ulcerative Proctitis, Proctosigmoiditis

Salix announced the completion and outcome of two Phase 3 studies evaluating the efficacy and safety of budesonide foam in the treatment of active mild to moderate ulcerative proctitis (UP) or ...
Yahoo Finance

First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

BOCA RATON, Fla., Sept. 28, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma", "First Wave", or the "Company"), a clinical ...
Yahoo Finance

First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative ...

BOCA RATON, Fla., Oct. 14, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the ...